HELP
Cybin Inc. Common Stock NASDAQ Listed Sep 13, 2019$8.59
+6.58%
vs $8.06
Mkt Cap $532.4M
52w Low $3.76
90.1% of range
52w High $9.12
50d MA $5.77
200d MA $6.09
P/E (TTM)
—
EV/EBITDA
—
P/B
0.7x
Debt/Equity
0.0x
ROE
—
P/FCF
-1.6x
RSI (14)
68.20
ATR (14)
$0.53
Beta
1.04
50d MA
$5.77
200d MA
$6.09
Avg Volume
1.8M
Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder
100 King Street West · Toronto, ON M5X 1C9 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | BMO | -0.83 | -0.96 | -15.5% | 6.88 | +0.0% | -3.9% | -5.0% | -0.6% | -5.6% | +2.4% | — |
| Feb 16, 2026 | AMC | -0.76 | -0.99 | -30.5% | — | — | — | — | — | — | — | — |
| Feb 13, 2026 | BMO | -0.53 | -0.72 | -35.8% | 6.09 | +5.1% | +11.0% | +5.0% | -2.8% | -1.3% | -1.2% | — |
| Nov 13, 2025 | BMO | -0.74 | -1.39 | -87.8% | — | — | — | — | — | — | — | — |
| Aug 13, 2025 | BMO | -0.96 | -1.10 | -14.7% | — | — | — | — | — | — | — | — |
| Jul 1, 2025 | BMO | -0.85 | -1.01 | -18.7% | — | — | — | — | — | — | — | — |
| Feb 11, 2025 | BMO | -0.73 | -0.37 | +49.5% | — | — | — | — | — | — | — | — |
| Nov 13, 2024 | BMO | -0.98 | -2.86 | -190.9% | — | — | — | — | — | — | — | — |
| Aug 8, 2024 | BMO | -0.97 | -0.12 | +88.0% | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | BMO | — | -0.17 | — | — | — | — | — | — | — | — | — |
| Feb 14, 2024 | BMO | -1.22 | -0.24 | +80.5% | — | — | — | — | — | — | — | — |
| Nov 15, 2023 | BMO | — | -0.05 | — | — | — | — | — | — | — | — | — |
| Aug 14, 2023 | BMO | — | -0.06 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.07 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 27 | Wells Fargo | Initiates | Overweight | $16 | $7.62 | $7.82 | +2.6% | +1.0% | -1.3% | +4.1% | +2.9% | -3.9% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.35 | $7.15 | -2.7% | +3.5% | +3.8% | +8.0% | -33.9% | -6.9% |
| Dec 3 | Guggenheim | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 20 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vr Adviser, Llc | 3,840,250 | $31M | New | Dec 2025 |
| 2 | Morgan Stanley | 2,599,512 | $21M | Added | Dec 2025 |
| 3 | Millennium Management | 2,415,841 | $12M | Added | Mar 2026 |
| 4 | Rosalind Advisors, Inc. | 1,531,814 | $7M | Reduced | Mar 2026 |
| 5 | Citadel Advisors Llc | 877,347 | $4M | Added | Mar 2026 |
| 6 | Nan Fung Group Holdings Ltd | 460,000 | $2M | — | Mar 2026 |
| 7 | Knott David M Jr | 350,000 | $2M | Added | Mar 2026 |
| 8 | Ubs Group Ag | 238,302 | $1M | Added | Mar 2026 |
| 9 | Hrt Financial Lp | 187,052 | $897K | New | Mar 2026 |
| 10 | Jane Street Group, Llc | 99,034 | $810K | Added | Dec 2025 |
| 11 | Susquehanna International Group, Llp | 147,925 | $710K | Reduced | Mar 2026 |
| 12 | Stonepine Capital Management, Llc | 134,060 | $643K | Reduced | Mar 2026 |
| 13 | Peak6 Llc | 62,597 | $300K | Reduced | Mar 2026 |
| 14 | Royal Bank Of Canada | 31,592 | $151K | Reduced | Mar 2026 |
| 15 | Adar1 Capital Management, Llc | 31,278 | $150K | New | Mar 2026 |
| 16 | Pds Planning, Inc | 30,344 | $145K | — | Mar 2026 |
| 17 | Axq Capital, Lp | 29,114 | $140K | New | Mar 2026 |
| 18 | Point72 Asset Management | 19,684 | $94K | Reduced | Mar 2026 |
| 19 | Centiva Capital, Lp | 10,000 | $48K | New | Mar 2026 |
| 20 | North Star Investment Management Corp. | 3,380 | $16K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF | 195,604 | $939K | Mar 2026 |
| 2 | Royce Smaller-Companies Growth Fund | 155,000 | $744K | Mar 2026 |
| 3 | Fidelity Nasdaq Composite Index Fund | 10,900 | $80K | Feb 2026 |
Valuation
Market Cap
$532.4M
Enterprise Value
$28.0M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.02x
P/B
0.73x
P/S
—
P/FCF
-1.58x
EV/EBITDA
—
Shares Out
20.2M
Financials (TTM)
Revenue
$0
Net Income
-$161.3M
EBITDA
-$153.8M
Free Cash Flow
-$103.3M
Op Cash Flow
-$101.3M
EPS Basic
$-0.61
EPS Diluted
$-5.72
EPS Forward
$-3.01
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$258.6M
Total Liab.
$21.4M
Total Equity
$237.2M
Cash
$135.0M
LT Debt
$0
Book Value/Sh
$11.73
Debt/Equity
0.00x
Current Ratio
7.75
Quick Ratio
7.75
Returns & Growth
ROE
—
ROA
—
ROIC
-60.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
+84.4%
Price Returns
2W
+13.4%
1M
+36.8%
3M
+52.4%
6M
+26.7%
12M
+36.4%
Technicals
52W High
$9.12
52W Low
$3.76
50d MA
$5.77
200d MA
$6.09
RSI (14)
68.20
ATR (14)
$0.53
Beta
1.04
Avg Volume
1.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$22.00
High
$22.00
Low
$22.00
Median
$22.00
Data updated apr 25, 2026 1:18pm
· Source: financialmodelingprep.com